D. In 2013, 35% of males between the ages of 13 and 17 years had received at least one dose of the vaccine.
In 2011, the percentage was 8%; in 2012, 21%; and in 2013 it was 35%. The ACIP made the recommendation to routinely vaccinate males in 2011 so the trend is moving in the right direction, but there is still a lot of room for improvement. Females have a higher rate of vaccination, as you might suspect for a vaccine heavily marketed to help prevent cervical cancer. In 2013, 57% of females between ages 13 and 17 years had received at least one dose.
Mom then asks you if the only benefit of HPV vaccine to her son will be the reduction in risk of contracting genital warts. Out of the corner of your eye, you see the 12-year-old dying a slow death at the mention of genital warts.
You tell her that the package insert (PI) says that the vaccine can reduce the risk of the following cancers caused by HPV types 16 or 18 (more than one answer may be correct):
A. Anal cancer
B. Penile cancer
C. Oropharyngeal cancers
Feel free to leave a comment first.
Markowitz LE, Dunne EF, Saraiya M, et al.; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014 Aug 29;63(RR-05):1-30.